P. Lampertico

机构：University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Ospedale Maggiore, IRCCS Policlinico San Donato, Policlinico Universitario di Catania, Politecnico di Milano

发表论文 4 篇 · 总被引 6 次 · h-index 1

代表论文

• LBA51 IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (2025 · Annals of Oncology · 被引 4)
• Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301 (2025 · Digestive and Liver Disease · 被引 1)
• Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data (2023 · Digestive and Liver Disease · 被引 1)
• Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta (2025 · Digestive and Liver Disease)